Cytarabine and cisplatin in advanced malignant melanoma.
Cancer Treat Rep
; 70(12): 1441-2, 1986 Dec.
Article
in En
| MEDLINE
| ID: mdl-3791257
Twenty-seven consecutive patients with advanced malignant melanoma were treated with cytarabine (Ara-C) and cisplatin. Of 25 evaluable patients, four achieved partial response, for a median duration of 3 months. Three of four responders belonged to the group of seven patients given Ara-C at a dose of 3 g/m2. The predominant toxic effect was hematologic and related to the dose of Ara-C. The cost-benefit ratio of this combination is inferior to that of dacarbazine or carmustine alone.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Melanoma
Limits:
Aged
/
Humans
Language:
En
Journal:
Cancer Treat Rep
Year:
1986
Document type:
Article
Country of publication:
United States